Beam Therapeutics Inc. (BEAM): debt financing — Beam Q4 net income $244.3M (full-year loss $80.0M); new PKU program; $500M Sixth Street credit facility

Beam Therapeutics Inc.

2025-FY EPS reported -$0.81 revenue$139,743,000

Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).
New liver-targeted program BEAM-304 for PKU; IND filing expected in 2026; targets two most prevalent PAH mutations.
$500M senior secured credit facility with Sixth Street; $100M funded at close; additional draws tied to risto-cel milestones.
Cash, cash equivalents and marketable securities $1.25B as of Dec 31, 2025; runway into mid-2029 with Sixth Street capital.
Risto-cel BLA submission expected as early as year-end 2026; BEAM-302 FDA alignment on accelerated approval path.

item 1.01 item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Beam Therapeutics Inc. incurred term loan of up to $500 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% f maturing February 24, 2033.

Instrument: term loan
Principal: up to $500 million
Counterparty: Sixth Street Lending Partners
Rate: 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% f
Maturity: February 24, 2033
Event: incurrence

Exact text from the filing

On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $500 million (the “Credit Facility”), consisting of (i) an initial draw of $100 million on the Closing Date,

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Beam Therapeutics Inc. entered into Financing Agreement with Sixth Street Lending Partners, as administrative agent and collateral agent valued at $500 million (effective 2026-02-24).

Action: entry
Agreement: credit facility
Counterparty: Sixth Street Lending Partners, as administrative agent and collateral agent
Value: $500 million
Effective: 2026-02-24

Exact text from the filing

On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders.

View on SEC.gov

Browse all debt financings →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-065191

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.